Oxford International, Le Montreux Palace, Montreux, Switzerland
06-08 June 2006
In keeping with Oxford International’s highly successful drug discovery series, an expert panel of speakers will convene to lead a full conference programme of more than 15 case study presentations, allowing attendees to gain an essential industry update. * STRATEGY: Integrating a translational approach to drug discovery: bridging the gap between discovery and development * TECHNOLOGIES: The emerging importance of –omics technologies: genomics, proteomics, metabolomics, pharmacogenomics Integrating predictive technologies such as biomarkers, HTS within discovery Optimising lead generation and validation Taking different approaches to discovery: employing structural biology and medicinal chemistry methodologies * INFORMATION MANAGEMENT: Achieving interoperability and integrating informatics, chem- and bio-informatics within discovery Handling multi-source data and integrating diverse IT solutions Knowledge Management * PRODUCTIVITY: Consolidating the discovery and development process: cutting costs, increasing efficiencies and maximising productivity * PORTFOLIO MANAGEMENT: Strategically managing the discovery portfolio: the business case for emerging technologies and achieving interoperability
|
|
Invited Speakers:
|
|
Confirmed Speakers: * Dr. Ismail Kola, Senior Vice President, Basic Research, Merck & Co. * Dr. Michel Pairet, Senior Vice President Research, Boehringer-Ingelheim Pharma GmbH & Co KG * Dr. Jeremy Everett, Vice President, Medical Technologies, Pfizer * Dr. Silvio Albertini, Deputy Head, Toxicology, F. Hoffmann-La Roche Ltd. * Dr. Greg Wiederrecht, Vice President and Head, External Scientific Affairs, Merck Research Labs * Dr. Chas Bountra, VP and Head of Biology, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline * Dr. Deborah Hartman, Director, Lead Generation, AstraZeneca * Dr. Kimber Hardy, Director, R&D Portfolio Management, Serono * Dr. Ulf Boemer, Head Technology Development & HTS Infrastructure, Schering AG * Dr. Sam Wadsworth, Vice President, Translational Research, Genzyme Pharmaceuticals * Dr. Wilma Keighley, Senior Director, Discovery Technologies, Pfizer * Dr. Juergen Hammer, Global Head Research IM; Head of Research Informatics, Genetics and Genomics, F. Hoffmann-La Roche * Dr. Steven Muchmore, Group Leader, Structural Biology, Abbott Laboratories * Senior Representative, Chemical Synthesis Services * Senior Representative, Invitrogen
|
|